In recent years the performance enhancement landscape has shifted faster than anti-doping agencies can adapt. What once revolved around anabolic steroids & growth hormone has evolved into a far more complex and far less regulated ecosystem of peptides and designer fragments marketed as safer and undetectable. The 2026 critical review A New Era of Doping? Use of Peptide and Peptide-Analog Drugs in Recreational & Professional Sport & Bodybuilding steps directly into this emerging frontier by dissecting the science & the growing risks behind these compounds. Drawing from clinical literature & anti-doping reports & real-world usage patterns the authors paint a picture of a rapidly expanding underground market where biological plausibility is often mistaken for evidence & where athletes are experimenting with substances that remain poorly studied and inconsistently manufactured and increasingly difficult to detect. Before we break down the methodology and strengths & limitations of the review its worth understanding why peptides have become the new currency of enhancement & why this shift matters for the future of sport.

A new era of doping? Use of peptide and peptide‑analog drugs in recreational and professional sport and bodybuilding: A critical review. The Journal of Sports Medicine and Physical Fitness. Advance online publication. Coutinho, L. F. D., de Oliveira Neves, L. F., & Camilo, R. P. (2026).

Introduction

This study presents peptide-based doping as the next big step forward in performance enhancement. The authors explain a change from traditional anabolic-androgenic steroids toward peptides and peptide analogues. These substances are heavily promoted as more targeted and more stable options that appear safer for building muscle and losing fat while improving recovery & reducing inflammation.

This shift is contextualized historically: doping has progressed from early stimulants to systemic steroid use, and now toward targeted signaling‑pathway manipulation via peptides. Unlike AAS, which act broadly through androgen receptors, peptides act on specific hormonal and metabolic pathways such as growth hormone release, lipolysis, and tissue repair.

The Core Problem Identified

Despite their popularity, the introduction emphasizes a major evidence gap:

•Most clinical studies examine peptides in therapeutic, medically supervised contexts.

•Bodybuilding and recreational use involve supraphysiological doses, stacking, and chronic exposure — none of which are represented in clinical trials.

•As a result, claims of muscle growth, fat loss, or recovery benefits remain biologically plausible but scientifically unproven.

The authors highlight emerging risks including cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability — concerns amplified by the unregulated supply chain, where mislabeling and contamination are common.

Anti‑Doping Landscape

The introduction also outlines the escalating challenge for anti‑doping agencies:

•Peptides are structurally similar to endogenous hormones.

•They have short half‑lives and rapid clearance.

•Detection requires advanced, evolving analytical methods.

WADA has expanded detection technologies, but the authors note that analytical limitations persist, making peptides attractive to athletes seeking undetectable enhancement.

A Critical Knowledge Gap

One of the most important points in the introduction is the lack of prevalence data:

•Recreational use is rising, driven by social media and “research chemical” vendors.

•Younger gym‑goers appear increasingly exposed.

•Yet no robust epidemiological studies exist to quantify usage.

The authors position this as a critical gap that limits public‑health understanding and policy development.

Study Design

Th…